Kilitch Drugs (India)NSE:KILITCH -0.61%84 Operating Margin % is 23.62% as of Mar. 2026, which is 109% above its 10-year median of 11.32. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹225.27 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 67.64% on this metric.
Kilitch Drugs (India) Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Kilitch Drugs (India)'s Operating Margin % or its related term are showing as below:
NSE:KILITCH'
s Operating Margin % Range Over the Past 10 Years
Min: -36.83 Med: 11.32 Max: 14.3
Current: 14
NSE:KILITCH's Operating Margin % is ranked better than 67.64% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs NSE:KILITCH: 14.00
Kilitch Drugs (India)'s 5-Year Average Operating Margin % Growth Rate was 20.30% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Kilitch Drugs (India) Operating Margin % Related Terms
Kilitch Drugs (India) Operating Margin % Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Operating Margin % distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Kilitch Drugs (India)'s Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a Operating Margin % of 23.62% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Kilitch Drugs (India) and its competitors. This is 109% above median its historical median of 11.32. According to the industry distribution chart, Kilitch Drugs (India) ranks #309 out of 955 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is Kilitch Drugs (India)'s Operating Margin % too high?
Kilitch Drugs (India)'s current Operating Margin % of 23.62% is 109% above median its 10-year median of 11.32. The Drug Manufacturers industry median Operating Margin % is 7.45. Kilitch Drugs (India)'s value of 23.62% is 217% above this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #309 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #309 out of 955 companies for Operating Margin %. This puts Kilitch Drugs (India) in the upper half of its industry. The industry median Operating Margin % is 7.45. Kilitch Drugs (India)'s value of 23.62% is 217% above this benchmark. While the company's 10-year median is 11.32 vs. the industry median of 7.45, Kilitch Drugs (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current Operating Margin % of 23.62% is 217% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current Operating Margin % is 23.62%, which is 109% above median its own 10-year median of 11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹225.27, compared to a current price of ₹185.31 — trading 17.7% below its estimated fair value. The current Operating Margin % is 23.62%, which is 109% above median its 10-year median of 11.32 and 217% above the Drug Manufacturers industry median of 7.45. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Operating Margin % is 23.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹185.31 is trading 17.7% below its estimated GF Value™ of ₹225.27.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Operating Margin %: 23.62% (109% above median its 10-year median of 11.32)
GF Value™: ₹225.27 vs. price of ₹185.31 (17.7% below fair value)
Industry Position: 217% above the Drug Manufacturers median (#309 of 955)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
